Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EBT (2017 - 2025)

Historic EBT for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $9.2 million.

  • Puma Biotechnology's EBT fell 5514.85% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year increase of 2532.64%. This contributed to the annual value of $24.1 million for FY2024, which is 628.91% up from last year.
  • Puma Biotechnology's EBT amounted to $9.2 million in Q3 2025, which was down 5514.85% from $6.2 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's EBT peaked at $20.6 million during Q3 2024, and registered a low of -$44.6 million during Q3 2021.
  • In the last 5 years, Puma Biotechnology's EBT had a median value of $3.3 million in 2025 and averaged $2.0 million.
  • Its EBT has fluctuated over the past 5 years, first surged by 215085.32% in 2023, then crashed by 39683.46% in 2024.
  • Quarter analysis of 5 years shows Puma Biotechnology's EBT stood at $4.4 million in 2021, then plummeted by 219.75% to -$5.3 million in 2022, then skyrocketed by 341.04% to $12.8 million in 2023, then fell by 4.42% to $12.2 million in 2024, then dropped by 24.47% to $9.2 million in 2025.
  • Its EBT stands at $9.2 million for Q3 2025, versus $6.2 million for Q2 2025 and $3.3 million for Q1 2025.